Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients

Angiogenesis

Volumn 9, Issue 2, 2006, Pages 73-81

  Parr, Christian ^a   Gan, Chun H ^a   Watkins, Gareth ^a   Jiang, Wen G ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Angiogenesis; Breast cancer; Prognosis; Real time quantitative PCR (Q PCR); TL1A; TNFSF15; Vascular endothelial growth inhibitor (VEGI)

Indexed keywords

TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH INHIBITOR;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GRADING; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM STAGING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33748971354     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10456-006-9033-1     Document Type: Article

References (39)

1. Althuis MD, Dozier JM, Anderson WF et al (2005) Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol 34:405-412
2. Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16:481-488
3. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6
4. Blood CH, Zetter BR (1990) Tumour interactions with the vasculature: angiogenesis and tumour metastasis. Biochim Biophys Acta 1032:89-118
5. Guidi AJ, Berry DA, Broadwater G et al (2000) Association of angiogenesis in lymph node metastases with outcome of breast cancer. J Natl Cancer Inst 92:486-492
6. Li J, Song ST, Jiang ZF et al (2003) Significance of microvascular density and vascular endothelial growth factor in breast cancer. Zhonghua Zhong Liu Za Zhi 25:145-148
7. Gasparini G (1996) Clinical significance of the determination of angiogenesis in human breast cancer: update of the biological background and overview of the Vincenza studies. Eur J Cancer 32:2485-2493
8. Weidner N, Folkman J, Pozza F et al (1992) Tumour angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma. J Natl Cancer Inst 84:1875-1887
9. Bosari S, Lee AK, DeLellis RA et al (1992) Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 23:755-761
10. Toi M, Kashitani J, Tominaga T (1991) Tumour angiogenesis is an independent prognostic indicator in primary breast carcinoma. N Engl J Med 324:1-8
11. Horak ER, Leek R, Klenk N et al (1992) Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340:1120-1124
12. Tsutsui S, Kume M, Era S (2003) Prognostic value of microvessel density in invasive ductal carcinoma of the breast. Breast Cancer 10:312-319
13. Toi M, Inada K, Suzuki H et al (1995) Tumour angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 36:193-204
14. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364
15. Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2:795-803
16. Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumour angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20:4368-4380
17. Maeda K, Chung YS, Ogawa Y et al (1996) Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 77:858-863
18. Zhang HT, Craft P, Scott PA et al (1995) Enhancement of tumour growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cell. J Natl Cancer Inst 87:213-219
19. Linderholm B, Tavelin B, Grankvist K et al (1998) Vascular endothelial growth factor is of high prognostic value in node negative breast carcinoma. J Clin Oncol 16:3121-3128
20. Gasparani G, Toi M, Gion M (1997) Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89:139-147
21. Zhai Y, Yu J, Iruela-Arispe L et al (1999) Inhibition of angiogenesis and breast cancer xenograft tumour growth by VEGI, a novel cytokine of the TNF superfamily. Int J Cancer 82:131-136
22. Shakibaei M, Schulze-Tanzil G, Takada Y et al (2005) Redox regulation of apoptosis by members of the TNF superfamily. Antioxid Redox Signal 7:482-496
23. Havell EA, Fiers W, North RJ (1990) The anti-tumour function of tumour necrosis factor (TNF). J Exp Med 167:1067-1085
24. Asher AL, Mule JJ, Reichert CM et al (1987) Studies on the anti-tumour efficacy of systemically administered recombinant tumour necrosis factor against several murine tumors in vivo. J Immunol 138:963-974
25. Zhai Y, Ni J, Jiang G et al (1999) VEGI, a novel cytokine of the tumour necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J 13:181-189
26. Migone TS, Zhang J, Luo X et al (2002) TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 16:479-492
27. Yang CR, Hsieh SL, Teng CM et al (2004) Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumour necrosis factor superfamily and exhibiting angiostatic action. Cancer Res 64:1122-1129
28. Parr C, Watkins G, Mansel RE et al (2004) The hepatocyte growth factor regulatory factors and human breast cancer. Clin Cancer Res 10:202-211
29. Jiang WG, Douglas-Jones A, Mansel RE (2003) Level of expression of PPAR-gamma and its co-activator (PPAR-GCA) in human breast cancer. Int J Cancer 106:752-757
30. Parr C, Jiang WG (2001) Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells. Int J Oncol 19:857-863
31. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27-31
32. Peter C, Rakesh KJ (2000) Angiogenesis in cancer and other diseases. Nature 407:249-257
33. Uzzan B, Nicolas P, Cucherat M et al (2004) Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 64:2941-2955
34. Carmeliet P (2000) Mechanisms of angiogenesis and arteriogenesis. Nat Med 6:389-395
35. Yu J, Tian S, Metheny-Barlow L et al (2001) Modulation of endothelial cell growth arrest and apoptosis by vascular endothelial growth inhibitor. Circ Res 89:1161-1167
36. Hou W, Medynski D, Wu S et al (2005) VEGI-192, a new isoform of TNFSF15, specifically eliminates tumour vascular endothelial cells and suppresses tumour growth. Clin Cancer Res 11:5595-5602
37. Chew LJ, Pan H, Yu J et al (2002) A novel secreted splice variant of vascular endothelial cell growth inhibitor. FASEB J 16:742-744
38. Lehmann W, Edgar CM, Wang K et al (2005) Tumour necrosis factor alpha (TNF-alpha) coordinately regulates the expression of specific matrix metalloproteinases (MMPS) and angiogenic factors during fracture healing. Bone 36:300-310
39. Xiao Q, Hsu CY, Chen H et al (2005) Characterization of cis-regulatory elements of the vascular endothelial growth inhibitor gene promoter. Biochem J 388:913-920